L’avis positif du CHMP se base sur les données de l’essai de Phase III CABINET, qui a consisté à étudier Cabometyx par rapport à un placebo chez des personnes atteintes de TNEp ou TNEep avancées, dont ...

CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen ...

The positive CHMP opinion is based on data from the CABINET Phase III trial, which investigated Cabometyx versus placebo in people living with advanced pNETs or epNETs, whose disease had progressed ...